Vuong, Nguyen Lam
Le Duyen, Huynh Thi
Lam, Phung Khanh
Tam, Dong Thi Hoai
Vinh Chau, Nguyen Van
Van Kinh, Nguyen
Chanpheaktra, Ngoun
Lum, Lucy Chai See
Pleités, Ernesto
Jones, Nick Keith
Simmons, Cameron Paul
Rosenberger, Kerstin
Jaenisch, Thomas
Halleux, Christine
Olliaro, Piero Luigi
Wills, Bridget
Yacoub, Sophie http://orcid.org/0000-0002-2910-7819
Funding for this research was provided by:
World Health Organization (UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases)
European Union (FP7-281803 IDAMS)
Article History
Received: 8 August 2019
Accepted: 13 January 2020
First Online: 17 February 2020
Ethics approval and consent to participate
: Ethical Committee approval was obtained from Oxford Tropical Research Ethics Committee (OxTREC) in the UK, and from all the local IRBs at each site for the original observational study. Further minimal risk applications were obtained for use of stored samples from OxTREC, and all other participating hospitals from which residual samples were selected. All patients signed an informed consent form in the original study, which included permission for future use of stored blood samples.
: Not applicable.
: SY receives consulting fees from Janssen pharmaceuticals for work on dengue antiviral development. All other authors declared that they have no competing interests. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.CH is staff of the World Health Organization. The authors alone are responsible for the views expressed in this article, and they do not necessarily represent the views, decisions, or policies of the institutions with which they are affiliated.